FDA Expands Remicade® (Infliximab) Psoriatic Arthritis Indication: Anti-TNF Shown To Inhibit Joint Damage And Improve Physical Function

... Centocor, Inc., announced that the U.S. Food and Drug Administration (FDA) has extended its approval for REMICADE® (infliximab) for inhibiting progression of structural damage and improving physical function in patients with psoriatic arthritis, in addition to reducing signs and symptoms of active arthritis. [click link for full article] ...